An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
2026年8月26日 更新者:Xentria, Inc.
A study of XTMAB-16 in patients with pulmonary sarcoidosis
研究概览
详细说明
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
研究类型
介入性
注册 (估计的)
182
阶段
- 阶段2
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Participant between 18 and 80 years (inclusive) of age.
- Weighs between 45 and 160 kg (99 to 353 lbs) at Screening.
- Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
- mMRC Dyspnea Scale of ≥1.
- Baseline pre-BD ppFVC of ≥ 50% during screening window, and confirmed at the Baseline visit prior to enrollment and dosing.
- Receiving corticosteroid treatment 5 to 25 mg/day of oral prednisone, or equivalent), during the screening period and, at the determination of the Investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
- Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
Radiographic evidence of disease in the lung parenchyma (at least Scadding stage II disease) without the presence of significant fibrosis.
Note: Significant fibrotic disease is defined as fibrosis > 20% as determined by central read.
- Able to provide written informed consent.
- In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements.
Exclusion Criteria:
- Pregnant or breastfeeding women or women who are planning to become pregnant during the study.
- Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by HRCT, confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included. A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a participant's last HRCT was from >6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review. Note: Significant fibrotic disease is defined as >20% fibrosis on HRCT.
- Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the Investigator.
- Any therapy with an anti-TNFα monoclonal antibody (e.g., infliximab, adalimumab, golimumab and their biosimilars) within 6 months.
- Baseline pre-BD ppFVC of >85%.
- Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.
- Clinically significant CNS sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.
- Advanced congestive heart failure (New York Heart Association 3 or 4).
- Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).
- Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.
- Known hypersensitivity to any component of the formulation of XTMAB-16.
- Evidence of active or latent tuberculosis (TB) by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.
- Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.
- Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.
- Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug. See Appendix 4 for details on contraception requirements during the study.
- Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug. See Appendix 4 for details on contraception requirements during the study.
- Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the Investigator.
- Any severe prior reaction to any type of biologics or human blood product such as albumin, immunoglobulin G (IgG), etc.
- Concurrent emphysema.
- Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the Investigator.
- Abnormal electrocardiogram (ECG): ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a corrected QT interval by Fredericia interval >450 ms (men) or >480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.
- Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.
- Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure (BP) ≥160/100 mmHg despite antihypertensive therapy within 3 months of randomization.
- Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.
- In the opinion of the Investigator, inability to tolerate corticosteroid taper.
- Concurrent systemic steroid use for non-sarcoidosis conditions.
- Concurrent known auto-immune disease requiring treatment.
- Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.
- Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.
- Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:XTMAB-16 4 mg/kg Q2W for 3 doses, then Q4W IV up to 52 weeks
|
Infusion
|
|
安慰剂比较:Placebo 4 mg/kg Q2W for 3 doses, then Q4W IV up to 52 weeks
|
输液
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 24
大体时间:Baseline to Week 24
|
To establish efficacy of XTMAB-16 as measured by FVC (mL) in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations(mL) in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 52
大体时间:Baseline to Week 52
|
To further establish efficacy of XTMAB-16 as measured by disease control in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Quality of Life King's Sarcoidosis Questionnaire-Lung (KSQ-L) mean change
大体时间:Baseline to Week 24 and 52
|
To further establish efficacy of XTMAB-16 as measured by quality of life in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24 and 52
|
|
Proportion of participants experiencing no independently adjudicated worsening (exacerbation) events through Week 52
大体时间:Baseline to Week 52
|
To further establish efficacy of XTMAB-16 as measured by disease control in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
King's Sarcoidosis Questionnaire - General (KSQ-G)
大体时间:Baseline to Week 24 and 52
|
To further establish efficacy of XTMAB-16 as measured by quality of life in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24 and 52
|
|
Modified Medical Research Council (mMRC) Dyspnea Scale
大体时间:Baseline to Week 24 and 52
|
To further establish efficacy of XTMAB-16 as measured by quality of life in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24 and 52
|
|
Fatigue Assessment Scale (FAS)
大体时间:Baseline to Week 24 and 52
|
To further establish efficacy of XTMAB-16 as measured by quality of life in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24 and 52
|
|
Time to first adjudicated worsening (exacerbation) event through Week 52
大体时间:Baseline to Week 52
|
To further establish efficacy of XTMAB-16 as measured by disease control in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Annualized worsening-event rate
大体时间:Baseline to Week 52
|
To further establish efficacy of XTMAB-16 as measured by disease control in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Mean number of worsening events per participant
大体时间:Baseline to Week 52
|
To further establish efficacy of XTMAB-16 as measured by disease control in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Imaging Endpoints High-resolution computed tomography (HRCT; 'worse,' 'no change,' or 'better')
大体时间:Baseline to Week 24 and 52
|
To further establish efficacy of XTMAB-16 as measured by imaging in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 24 and 52
|
|
Maximum observed concentration (Cmax)
大体时间:Baseline to Week 52
|
To characterize the Pharmacokinetics (PK) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Clearence
大体时间:Baseline to Week 52
|
To characterize the Pharmacokinetics (PK) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Volume Parameters
大体时间:Baseline to Week 52
|
To characterize the Pharmacokinetics (PK) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
|
Soluble tumor necrosis factor alpha (sTNFα)
大体时间:Baseline to Week 12, 24 and 52
|
To characterize the Pharmacodynamics (PD) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 12, 24 and 52
|
|
Interleukin-1beta (IL-1β)
大体时间:Baseline to Week 12, 24 and 52
|
To characterize the Pharmacodynamics (PD) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 12, 24 and 52
|
|
Soluble IL-2 receptor (sIL-2R)
大体时间:Baseline to Week 12, 24 and 52
|
To characterize the Pharmacodynamics (PD) of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 12, 24 and 52
|
|
Number and percentage of participants who test positive for anti-drug antibody (ADA) at Baseline and transient and persistent positive status at Weeks 12, 24, and 52.
大体时间:Baseline to Week 12, 24 and 52
|
To characterize the immunogenicity of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 12, 24 and 52
|
|
Number and percentage of participants who test positive for neutralizing antibody (nAb) at Baseline and transient and persistent positive status at Weeks 12, 24, and 52.
大体时间:Baseline to Week 12, 24 and 52
|
To characterize the immunogenicity of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 12, 24 and 52
|
|
Adverse event (AE) assessments
大体时间:Baseline to Week 52
|
To evaluate continued safety and tolerability of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations
|
Baseline to Week 52
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年10月30日
初级完成 (估计的)
2029年10月31日
研究完成 (估计的)
2029年10月31日
研究注册日期
首次提交
2026年6月25日
首先提交符合 QC 标准的
2026年6月25日
首次发布 (实际的)
2026年7月2日
研究记录更新
最后更新发布 (实际的)
2026年8月31日
上次提交的符合 QC 标准的更新
2026年8月26日
最后验证
2026年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.